DDInter948 DDInter667
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Erlotinib {u} (Compound) resembles {v} (Compound) Vandetanib
Erlotinib {u} (Compound) resembles {v} (Compound) Gefitinib
Erlotinib {u} (Compound) treats {v} (Disease) kidney cancer
Erlotinib {u} (Compound) binds {v} (Gene) CYP1A2
Erlotinib {u} (Compound) upregulates {v} (Gene) IL1B
Erlotinib {u} (Compound) downregulates {v} (Gene) COX8A
Erlotinib {u} (Compound) causes {v} (Side Effect) Drug interaction
Erlotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Erlotinib (Compound) resembles Vandetanib (Compound)
Erlotinib (Compound) resembles Gefitinib (Compound)
Erlotinib (Compound) treats kidney cancer (Disease)
Erlotinib (Compound) binds CYP1A2 (Gene)
Erlotinib (Compound) upregulates IL1B (Gene)
Erlotinib (Compound) downregulates COX8A (Gene)
Erlotinib (Compound) causes Drug interaction (Side Effect)
Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine